Alphamab Oncology's (HKG:9966) loss widened to 44.9 million yuan in the first half from 40.4 million yuan in the year-ago period, according to a Thursday filing with the Hong Kong Stock Exchange.
Loss per share at the biopharmaceutical company widened to 0.05 yuan from 0.04 yuan in the previous year.
Revenue grew to 173.6 million yuan from 136.5 million yuan a year earlier. Other gains plunged to 7.3 million yuan from 48.8 million yuan a year earlier.
Shares surged 7% during Friday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments